Jon M Wigginton

List of Publications by Year
in descending order

30 papers	26,754 citations	279798 23 h-index	526287 27 g-index
30 all docs	30 docs citations	30 times ranked	29482 citing authors

#	Article	IF	Citations
1	Combination immunotherapy: a road map. , 2017, 5, 16.		325
2	The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting. , 2017, 5, .		11
3	Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. , 2017, 5, 44.		181
4	Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. Journal of Clinical Oncology, 2015, 33, 2013-2020.	1.6	385
5	Overall Survival and Long-Term Safety of Nivolumab (Antiâ€"Programmed Death 1 Antibody, BMS-936558,) Tj ETQq1 1 0.784314 rgBT / Clinical Oncology, 2015, 33, 2004-2012.	1.6	1,035
6	Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab. Journal of Clinical Oncology, 2014, 32, 1020-1030.	1.6	2,015
7	Nivolumab plus Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 2013, 369, 122-133.	27.0	3,776
8	Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538).. Journal of Clinical Oncology, 2013, 31, CRA9006-CRA9006.	1.6	41
9	Safety, Activity, and Immune Correlates of Antiâ€"PD-1 Antibody in Cancer. New England Journal of Medicine, 2012, 366, 2443-2454.	27.0	10,727
10	High-Throughput Molecular and Histopathologic Profiling of Tumor Tissue in a Novel Transplantable Model of Murine Neuroblastoma: New Tools for Pediatric Drug Discovery. Cancer Investigation, 2012, 30, 343-363.	1.3	9
11	Safety and Activity of Antiâ€"PD-L1 Antibody in Patients with Advanced Cancer. New England Journal of Medicine, 2012, 366, 2455-2465.	27.0	6,820
12	Defining the critical hurdles in cancer immunotherapy. Journal of Translational Medicine, 2011, 9, 214.	4.4	139
13	Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages. Immunology, 2011, 132, 226-239.	4.4	111
14	Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clinical Cancer Research, 2011, 17, 3064-3076.	7.0	108
15	Immunologic and Therapeutic Synergy of IL-27 and IL-2: Enhancement of T Cell Sensitization, Tumor-Specific CTL Reactivity and Complete Regression of Disseminated Neuroblastoma Metastases in the Liver and Bone Marrow. Journal of Immunology, 2009, 182, 4328-4338.	0.8	90
16	Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opinion on Biological Therapy, 2007, 7, 1705-1721.	3.1	191
17	Multicolor Fluorescence-Based Approaches for Imaging Cytokine-Induced Alterations in the Neovascularization, Growth, Metastasis, and Apoptosis of Murine Neuroblastoma Tumors. Journal of Immunotherapy, 2006, 29, 151-164.	2.4	8
18	Therapeutic Modulation of Akt Activity and Antitumor Efficacy of Interleukin-12 Against Orthotopic Murine Neuroblastoma. Journal of the National Cancer Institute, 2006, 98, 190-202.	6.3	13

#	Article	IF	Citations
19	Proteasome Inhibition to Maximize the Apoptotic Potential of Cytokine Therapy for Murine Neuroblastoma Tumors. Journal of Immunology, 2006, 176, 6302-6312.	0.8	32
20	IL-27 Mediates Complete Regression of Orthotopic Primary and Metastatic Murine Neuroblastoma Tumors: Role for CD8+ T Cells. Journal of Immunology, 2004, 173, 7170-7182.	0.8	151
21	Synergistic Anti-Tumor Responses After Administration of Agonistic Antibodies to CD40 and IL-2: Coordination of Dendritic and CD8+ Cell Responses. Journal of Immunology, 2003, 170, 2727-2733.	0.8	105
22	Synergistic Engagement of an Ineffective Endogenous Anti-Tumor Immune Response and Induction of IFN-Î³ and Fas-Ligand-Dependent Tumor Eradication by Combined Administration of IL-18 and IL-2. Journal of Immunology, 2002, 169, 4467-4474.	0.8	66
23	IL-12/IL-2 combination cytokine therapy for solid tumours: translation from bench to bedside. Expert Opinion on Biological Therapy, 2002, 2, 513-524.	3.1	43
24	Primary Hepatocytes from Mice Treated with IL-2/IL-12 Produce T Cell Chemoattractant Activity that Is Dependent on Monokine Induced by IFN-Î³ (Mig) and Chemokine Responsive to Î³-2 (Crg-2). Journal of Immunology, 2001, 166, 3763-3770.	0.8	33
25	Complete Regression of Established Spontaneous Mammary Carcinoma and the Therapeutic Prevention of Genetically Programmed Neoplastic Transition by IL-12/Pulse IL-2: Induction of Local T Cell Infiltration, Fas/Fas Ligand Gene Expression, and Mammary Epithelial Apoptosis. Journal of Immunology, 2001, 166, 1156-1168.	0.8	48
26	IFN-Î³ and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. Journal of Clinical Investigation, 2001, 108, 51-62.	8.2	110
27	IFN-Î³-Dependent Delay of In Vivo Tumor Progression by Fas Overexpression on Murine Renal Cancer Cells. Journal of Immunology, 2000, 164, 231-239.	0.8	69
28	Interleukin-12: Murine Models of a Potent Antitumor Agent. Annals of the New York Academy of Sciences, 1996, 795, 266-274.	3.8	26
29	Evaluation of the Antitumor Activity of the Interleukin-12/Pulse Interleukin-2 Combination. Annals of the New York Academy of Sciences, 1996, 795, 434-439.	3.8	9
30	Antitumor activity of interleukin 12 in preclinical models. Cancer Chemotherapy and Pharmacology, 1996, 38, S16-S21.	2.3	77